JAK/STAT inhibitors and other small molecule cytokine antagonists for the treatment of allergic disease

Annals of Allergy, Asthma and Immunology

Volumn 120, Issue 4, 2018, Pages 367-375

  Howell, Michael D ^a   Fitzsimons, Carolyn ^a   Smith, Paul A ^a  

^a Drug Metabolism Pharmacokinetics Clinical Pharmacology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 6 [3 (DIMETHYLCARBAMOYL)PHENYLSULFONYL] 4 (3 METHOXYANILINO) 8 METHYL 3 QUINOLINECARBOXAMIDE; APREMILAST; AZD 1981; BARICITINIB; BI 671800; CELGENE; CETIRIZINE; CHEMOATTRACTANT; CHEMOKINE RECEPTOR ANTAGONIST; CYTOKINE RECEPTOR ANTAGONIST; FEVIPIPRANT; IMATINIB; JANUS KINASE; JANUS KINASE INHIBITOR; PF 04965842; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PROTEIN INHIBITOR; QAV 680; ROFLUMILAST; SETIPIPRANT; TIMAPIPRANT; TOFACITINIB; UPADACITINIB; VIDUPIPRANT; CYTOKINE; STAT PROTEIN;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; BRONCHUS HYPERREACTIVITY; DOWNSTREAM PROCESSING; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; HUMAN; IMMUNOMODULATION; INFLAMMATION; NONHUMAN; PATHOGENESIS; PHENOTYPE; POLLEN ALLERGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TH2 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; HYPERSENSITIVITY;

ANIMALS; CYTOKINES; HUMANS; HYPERSENSITIVITY; JANUS KINASE INHIBITORS; STAT TRANSCRIPTION FACTORS;

EID: 85044666784     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2018.02.012     Document Type: Review

References (104)

1. Pawankar, R., Canonica, G.W., Holgate, S.T., Lockey, R.F., Blaiss, M., World Allergy Organization (WAO) white book on allergy. Update, 2013 http://www.worldallergy.org/UserFiles/file/ExecSummary-2013-v6-hires.pdf. (Accessed 16 October 2017)
2. Zuberbier, T., Lotvall, J., Simoens, S., Subramanian, S.V., Church, M.K., Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review. Allergy 69 (2014), 1275–1279.
3. Zheng, T., Yu, J., Oh, M.H., Zhu, Z., The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. Allergy Asthma Immunol Res 3 (2011), 67–73.
4. Lio, P.A., Lee, M., LeBovidge, J., Timmons, K.G., Schneider, L., Clinical management of atopic dermatitis: practical highlights and updates from the atopic dermatitis practice parameter 2012. J Allergy Clin Immunol Pract 2 (2014), 361–369 quiz 370.
5. Muraro, A., Lemanske, R.F. Jr, Hellings, P.W., et al. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis—PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 137 (2016), 1347–1358.
6. Regan, J.A., Cao, Y., Dispenza, M.C., et al. Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity. J Allergy Clin Immunol 140 (2017), 875–879 e871.
7. Duan, W., Aguinaldo Datiles, A.M., Leung, B.P., Vlahos, C.J., Wong, W.S., An anti–inflammatory role for a phosphoinositide 3-kinase inhibitor LY294002 in a mouse asthma model. Int Immunopharmacol 5 (2005), 495–502.
8. Huang, P., Li, Y., Lv, Z., et al. Comprehensive attenuation of IL-25-induced airway hyperresponsiveness, inflammation and remodelling by the PI3K inhibitor LY294002. Respirology 22 (2017), 78–85.
9. Cahill, K.N., Katz, H.R., Cui, J., et al. KIT inhibition by imatinib in patients with severe refractory asthma. N Engl J Med 376 (2017), 1911–1920.
10. Villarino, A.V., Kanno, Y., O'Shea, J.J., Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol 18 (2017), 374–384.
11. Stark, G.R., Cheon, H., Wang, Y., Responses to cytokines and interferons that depend upon JAKs and STATs. Cold Spring Harb Perspect Biol, 10, 2018.
12. Macchi, P., Villa, A., Giliani, S., et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377 (1995), 65–68.
13. Russell, S.M., Tayebi, N., Nakajima, H., et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270 (1995), 797–800.
14. Holland, S.M., DeLeo, F.R., Elloumi, H.Z., et al. STAT3 mutations in the Hyper-IgE syndrome. N Engl J Med 357 (2007), 1608–1619.
15. Hsieh, Y.Y., Chang, C.C., Hsu, C.M., et al. JAK-1 rs2780895 C-related genotype and allele but not JAK-1 rs10789166, rs4916008, rs2780885, rs17127114, and rs3806277 are associated with higher susceptibility to asthma. Genet Test Mol Biomarkers 15 (2011), 841–847.
16. Jiang, X.Y., Zhao, J.H., Yu, C.X., et al. Association analyses identify two susceptibility loci 5q31 and 5q22.1 for atopic dermatitis in Chinese Han population. Asian Pac J Allergy Immunol 35 (2017), 196–202.
17. Shen, Y., Liu, Y., Ke, X., Kang, H.Y., Hu, G.H., Hong, S.L., Association between JAK1 gene polymorphisms and susceptibility to allergic rhinitis. Asian Pac J Allergy Immunol 34 (2016), 124–129.
18. Gandhi, N.A., Bennett, B.L., Graham, N.M., Pirozzi, G., Stahl, N., Yancopoulos, G.D., Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 15 (2016), 35–50.
19. Rochman, Y., Kashyap, M., Robinson, G.W., et al. Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling. Proc Natl Acad Sci USA 107 (2010), 19455–19460.
20. Levy, L.L., Urban, J., King, B.A., Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol 73 (2015), 395–399.
21. Busse, W.W., Wenzel, S.E., Meltzer, E.O., et al. Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients. J Allergy Clin Immunol 131 (2013), 339–345.
22. Barnes, N., Pavord, I., Chuchalin, A., et al. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy 42 (2012), 38–48.
23. Singh, D., Cadden, P., Hunter, M., et al. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459. Eur Respir J 41 (2013), 46–52.
24. Horak, F., Zieglmayer, P., Zieglmayer, R., et al. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial. Allergy 67 (2012), 1572–1579.
25. Miller, D., Wood, C., Bateman, E., et al. A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma. Allergy Asthma Proc 38 (2017), 157–164.
26. Hall, I.P., Fowler, A.V., Gupta, A., et al. Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment. Pulm Pharmacol Ther 32 (2015), 37–44.
27. Krug, N., Gupta, A., Badorrek, P., et al. Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis. J Allergy Clin Immunol 133 (2014), 414–419.
28. Erpenbeck, V.J., Popov, T.A., Miller, D., et al. The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma. Pulm Pharmacol Ther 39 (2016), 54–63.
29. Gonem, S., Berair, R., Singapuri, A., et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med 4 (2016), 699–707.
30. Bateman, E.D., Guerreros, A.G., Brockhaus, F., et al. Fevipiprant, an oral prostaglandin DP2 receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroids. Eur Respir J, 50, 2017.
31. Kuna, P., Bjermer, L., Tornling, G., Two phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma. Drug Des Devel Ther 10 (2016), 2759–2770.
32. Ratner, P., Andrews, C.P., Hampel, F.C., et al. Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from phase 2 and phase 3 randomized, double-blind, placebo- and active-referenced studies. Allergy Asthma Clin Immunol, 13, 2017, 18.
33. Samrao, A., Berry, T.M., Goreshi, R., Simpson, E.L., A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol 148 (2012), 890–897.
34. Volf, E.M., Au, S.C., Dumont, N., Scheinman, P., Gottlieb, A.B., A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol 11 (2012), 341–346.
35. Singh, D., Petavy, F., Macdonald, A.J., Lazaar, A.L., O'Connor, B.J., The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res, 11, 2010, 26.
36. van Schalkwyk, E., Strydom, K., Williams, Z., et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 116 (2005), 292–298.
37. Gauvreau, G.M., Boulet, L.P., Schmid-Wirlitsch, C., et al. Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respir Res, 12, 2011, 140.
38. Louw, C., Williams, Z., Venter, L., et al. Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge. Respiration 74 (2007), 411–417.
39. Bateman, E.D., Izquierdo, J.L., Harnest, U., et al. Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol 96 (2006), 679–686.
40. Bousquet, J., Aubier, M., Sastre, J., et al. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy 61 (2006), 72–78.
41. Schmidt, B.M., Kusma, M., Feuring, M., et al. The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis. J Allergy Clin Immunol 108 (2001), 530–536.
42. Kostenis, E., Ulven, T., Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol Med 12 (2006), 148–158.
43. Lipworth, B.J., Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365 (2005), 167–175.
44. Jin, S.L., Ding, S.L., Lin, S.C., Phosphodiesterase 4 and its inhibitors in inflammatory diseases. Chang Gung Med J 35 (2012), 197–210.
45. Essayan, D.M., Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem Pharmacol 57 (1999), 965–973.
46. Pieretti, S., Dominici, L., Di Giannuario, A., Cesari, N., Dal Piaz, V., Local anti-inflammatory effect and behavioral studies on new PDE4 inhibitors. Life Sci 79 (2006), 791–800.
47. Hidi, R., Timmermans, S., Liu, E., et al. Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis. Eur Respir J 15 (2000), 342–349.
48. Giembycz, M.A., Corrigan, C.J., Seybold, J., Newton, R., Barnes, P.J., Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 118 (1996), 1945–1958.
49. Hanifin, J.M., Reed, M.L., A population-based survey of eczema prevalence in the United States. Dermatitis 18 (2007), 82–91.
50. Silverberg, J.I., Simpson, E.L., Associations of childhood eczema severity: a US population-based study. Dermatitis 25 (2014), 107–114.
51. Spergel, J.M., From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol 105 (2010), 99–106 quiz 107–109, 117.
52. Kulig, M., Bergmann, R., Klettke, U., Wahn, V., Tacke, U., Wahn, U., Natural course of sensitization to food and inhalant allergens during the first 6 years of life. J Allergy Clin Immunol 103 (1999), 1173–1179.
53. Gustafsson, D., Sjoberg, O., Foucard, T., Development of allergies and asthma in infants and young children with atopic dermatitis: a prospective follow-up to 7 years of age. Allergy 55 (2000), 240–245.
54. Silverberg, J.I., Hanifin, J.M., Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol 132 (2013), 1132–1138.
55. Sehra, S., Yao, Y., Howell, M.D., et al. IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. J Immunol 184 (2010), 3186–3190.
56. Albanesi, C., Fairchild, H.R., Madonna, S., et al. IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3. J Immunol 179 (2007), 984–992.
57. Ong, P.Y., Ohtake, T., Brandt, C., et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347 (2002), 1151–1160.
58. Howell, M.D., Wollenberg, A., Gallo, R.L., et al. Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol 117 (2006), 836–841.
59. Brauweiler, A.M., Goleva, E., Leung, D.Y.M., Th2 cytokines increase Staphylococcus aureus alpha toxin-induced keratinocyte death through the signal transducer and activator of transcription 6 (STAT6). J Invest Dermatol 134 (2014), 2114–2121.
60. Simon, D., Braathen, L.R., Simon, H.U., Eosinophils and atopic dermatitis. Allergy 59 (2004), 561–570.
61. Molfino, N.A., Gossage, D., Kolbeck, R., Parker, J.M., Geba, G.P., Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy 42 (2012), 712–737.
62. Dillon, S.R., Sprecher, C., Hammond, A., et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 5 (2004), 752–760.
63. Niyonsaba, F., Ushio, H., Hara, M., et al. Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells. J Immunol 184 (2010), 3526–3534.
64. Comeau, M.R., Ziegler, S.F., The influence of TSLP on the allergic response. Mucosal Immunol 3 (2010), 138–147.
65. Wilson, S.R., The, L., Batia, L.M., et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell 155 (2013), 285–295.
66. Boniface, K., Bernard, F.X., Garcia, M., Gurney, A.L., Lecron, J.C., Morel, F., IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 174 (2005), 3695–3702.
67. Wolk, K., Witte, E., Witte, K., Warszawska, K., Sabat, R., Biology of interleukin-22. Semin Immunopathol 32 (2010), 17–31.
68. AbbVie, EADV 2017 – Abstracts [press release from AbbVie]. North Chicago, IL: AbbVie, 2017.
69. Jessup, H.K., Brewer, A.W., Omori, M., et al. Intradermal administration of thymic stromal lymphopoietin induces a T cell- and eosinophil-dependent systemic Th2 inflammatory response. J Immunol 181 (2008), 4311–4319.
70. Chevalier, E., Stock, J., Fisher, T., et al. Cutting edge: chemoattractant receptor-homologous molecule expressed on Th2 cells plays a restricting role on IL-5 production and eosinophil recruitment. J Immunol 175 (2005), 2056–2060.
71. Boehme, S.A., Chen, E.P., Franz-Bacon, K., et al. Antagonism of CRTH2 ameliorates chronic epicutaneous sensitization-induced inflammation by multiple mechanisms. Int Immunol 21 (2009), 1–17.
72. Hijnen, D., Nijhuis, E., Bruin-Weller, M., et al. Differential expression of genes involved in skin homing, proliferation, and apoptosis in CD4+ T cells of patients with atopic dermatitis. J Invest Dermatol 125 (2005), 1149–1155.
73. Iwasaki, M., Nagata, K., Takano, S., Takahashi, K., Ishii, N., Ikezawa, Z., Association of a new-type prostaglandin D2 receptor CRTH2 with circulating T helper 2 cells in patients with atopic dermatitis. J Invest Dermatol 119 (2002), 609–616.
74. Hanifin, J.M., Chan, S.C., Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. J Invest Dermatol 105 (1995), 84S–88S.
75. Gantner, F., Tenor, H., Gekeler, V., Schudt, C., Wendel, A., Hatzelmann, A., Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study. J Allergy Clin Immunol 100 (1997), 527–535.
76. Paller, A.S., Tom, W.L., Lebwohl, M.G., et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 75 (2016), 494–503 e496.
77. World Health Organization, Global Surveillance, Prevention and Control of Chronic Respiratory Diseases: A Comprehensive Approach. 2007, World Health Organization, Geneva, Switzerland http://www.who.int/gard/publications/GARD%20Book%202007.pdf. (Accessed 16 October 2017)
78. Eriksson, J., Ekerljung, L., Bossios, A., et al. Aspirin-intolerant asthma in the population: prevalence and important determinants. Clin Exp Allergy 45 (2015), 211–219.
79. Gilmour, M.I., Jaakkola, M.S., London, S.J., Nel, A.E., Rogers, C.A., How exposure to environmental tobacco smoke, outdoor air pollutants, and increased pollen burdens influences the incidence of asthma. Environ Health Perspect 114 (2006), 627–633.
80. Corren, J., Asthma phenotypes and endotypes: an evolving paradigm for classification. Discov Med 15 (2013), 243–249.
81. Ray, A., Raundhal, M., Oriss, T.B., Ray, P., Wenzel, S.E., Current concepts of severe asthma. J Clin Invest 126 (2016), 2394–2403.
82. Elias, J.A., Lee, C.G., Zheng, T., Ma, B., Homer, R.J., Zhu, Z., New insights into the pathogenesis of asthma. J Clin Invest 111 (2003), 291–297.
83. Fahy, J.V., Type 2 inflammation in asthma: present in most, absent in many. Nat Rev Immunol 15 (2015), 57–65.
84. Raundhal, M., Morse, C., Khare, A., et al. High IFN-gamma and low SLPI mark severe asthma in mice and humans. J Clin Invest 125 (2015), 3037–3050.
85. Vanaudenaerde, B.M., Verleden, S.E., Vos, R., et al. Innate and adaptive interleukin-17-producing lymphocytes in chronic inflammatory lung disorders. Am J Respir Crit Care Med 183 (2011), 977–986.
86. O'Shea, J.J., Plenge, R., JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36 (2012), 542–550.
87. Kudlacz, E., Conklyn, M., Andresen, C., Whitney-Pickett, C., Changelian, P., The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia. Eur J Pharmacol 582 (2008), 154–161.
88. Aguilar-Pimentel, A., Graessel, A., Alessandrini, F., et al. Improved efficacy of allergen-specific immunotherapy by JAK inhibition in a murine model of allergic asthma. PLoS ONE, 12, 2017 e0178563.
89. Southworth, T., Plumb, J., Gupta, V., et al. Anti-inflammatory potential of PI3Kdelta and JAK inhibitors in asthma patients. Respir Res, 17, 2016, 124.
90. Pettipher, R., Hunter, M.G., Perkins, C.M., et al. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy 69 (2014), 1223–1232.
91. Diamant, Z., Sidharta, P.N., Singh, D., et al. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy 44 (2014), 1044–1052.
92. Spina, D., Theophylline and PDE4 inhibitors in asthma. Curr Opin Pulm Med 9 (2003), 57–64.
93. Boswell-Smith, V., Cazzola, M., Page, C.P., Are phosphodiesterase 4 inhibitors just more theophylline?. J Allergy Clin Immunol 117 (2006), 1237–1243.
94. Beghe, B., Rabe, K.F., Fabbri, L.M., Phosphodiesterase-4 inhibitor therapy for lung diseases. Am J Respir Crit Care Med 188 (2013), 271–278.
95. Adamia, N., Manjavidze, N., Ghughunishvili, M., et al. PO-0990 prevalence of allergic rhinitis in children's population—Adjara region. Arch Dis Child, 99, 2014, A574.
96. Chiang, W.C., Chen, Y.M., Tan, H.K., et al. Allergic rhinitis and non-allergic rhinitis in children in the tropics: prevalence and risk associations. Pediatr Pulmonol 47 (2012), 1026–1033.
97. Law, A.W., Reed, S.D., Sundy, J.S., Schulman, K.A., Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey. J Allergy Clin Immunol 111 (2003), 296–300.
98. Sullivan, S.D., Weiss, K.B., Health economics of asthma and rhinitis. II. Assessing the value of interventions. J Allergy Clin Immunol 107 (2001), 203–210.
99. Holgate, S.T., Broide, D., New targets for allergic rhinitis—a disease of civilization. Nat Rev Drug Discov 2 (2003), 902–914.
100. Seidman, M.D., Gurgel, R.K., Lin, S.Y., et al. Clinical practice guideline: allergic rhinitis. Otolaryngol Head Neck Surg 152 (2015), S1–S43.
101. Durham, S.R., Creticos, P.S., Nelson, H.S., et al. Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: pooled analyses. J Allergy Clin Immunol 138 (2016), 1081–1088 e1084.
102. Bernstein, D.I., Schwartz, G., Bernstein, J.A., Allergic rhinitis: mechanisms and treatment. Immunol Allergy Clin North Am 36 (2016), 261–278.
103. Hunter, M.G., Pettipher, E.R., Perkins, C.M., Payton, M.A., Xue, L., (Oxagen) Use of CRTH2 antagonist compounds. PCT Int Appl, 2009 WO2009063215.
104. Willard, L., Brown, Z., Owen, C., Dubois, G., Characterization of QAW039 and QAV680, two novel, potent and selective CRTh2 antagonists. Eur Respir J, 44, 2014, P4072.